| BRIEF COMMUNICATION |
|
| Year : 2015 | Volume
: 19
| Issue : 3 | Page : 426-429 |
|
|
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
Sanjay Kalra1, Yashdeep Gupta2, Shiva Patil3
1 Department of Endocrinology, Bharti Hospital and B.R.I.D.E, Karnal, Haryana, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India
3 Senior Medical Advisor, Boehringer Ingelheim, Mumbai, India
Correspondence Address:
Sanjay Kalra
Executive Editor, Indian J Endocrinology and Metabolism, Bharti Hospital and B.R.I.D.E, Karnal - 132 001, Haryana
India
 Source of Support: Dr. Shiva Patil works as Senior Medical Advisor with
Boehringer Ingelheim India Private Limited. However, the views expressed by
him in this commentary are in his personal capacity as an MD in Pharmacology
and not as an employee of Boehringer Ingelheim India., Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.152793
|
|
|
The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of glucose-lowering drugs which act by inhibiting the reabsorption of filtered glucose from the kidneys. Their effect on insulin and glucagon levels has recently been studied but is not fully explained. This communication proposes various hypotheses: A direct effect of SGLT-2 inhibition on the alpha cell receptors, a paracrine or intra-islet mediated effect on alpha cell sensitivity to glucose, and a calorie restriction mimetic action, to explain the impact of these drugs on the insulin glucagon ratio. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
